These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 13679589)

  • 1. Liposomal anthracyclines for breast cancer: overview.
    O'Shaughnessy J
    Oncologist; 2003; 8 Suppl 2():1-2. PubMed ID: 13679589
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal anthracyclines in metastatic breast cancer: clinical update.
    Rivera E
    Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer.
    Campos S
    Oncologist; 2003; 8 Suppl 2():10-6. PubMed ID: 13679591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac safety of liposomal anthracyclines.
    Safra T
    Oncologist; 2003; 8 Suppl 2():17-24. PubMed ID: 13679592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 6. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
    Aapro MS
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
    Coltelli L; Fontana A; Lucchesi S; Ginocchi L; Bocci G; Filidei M; Scalese M; Arrighi G; Finale C; Marcucci L; Goletti O; Salvadori B; Ferrarini I; Bona E; Falcone A; Allegrini G
    Breast; 2017 Feb; 31():186-191. PubMed ID: 27886643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Curtit E; Nouyrigat P; Dohollou N; Levy E; Lortholary A; Gligorov J; Facchini T; Jaubert D; Maille N; Pivot X; Grangé V; Cals L
    Eur J Cancer; 2011 Nov; 47(16):2396-402. PubMed ID: 21920729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal anthracyclines for breast cancer.
    Sparano JA; Winer EP
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect.
    Kalra R; Chavada B; Madhani NR; Purohit B; Tripathi CB
    Curr Drug Saf; 2018; 13(1):62-64. PubMed ID: 28933276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal anthracyclines and new treatment approaches for breast cancer.
    Wolff AC
    Oncologist; 2003; 8 Suppl 2():25-30. PubMed ID: 13679593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 20. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.